Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.

You may also be interested in...



Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies

Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.

Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing

Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.

Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation

Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel